TPBG
CRSP icon

Turning Point Benefit Group’s CRISPR Therapeutics CRSP Stock Holding History

Turning Point Benefit Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8
Closed -$419 – 253
2025
Q4 		$419 Buy
+8
New +$479 ﹤0.01% 666

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Turning Point Benefit Group's CRSP Position: Q1 2026 in Review

Turning Point Benefit Group sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 8 shares — an estimated $419 sold.

Turning Point Benefit Group first reported a position in CRSP in Q4 2025 and held it in 1 quarter. The position peaked at $419 in Q4 2025. 492 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Turning Point Benefit Group reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Turning Point Benefit Group sold 8 CRISPR Therapeutics shares in Q1 2026, an estimated $419.
  • Turning Point Benefit Group first reported a position in CRISPR Therapeutics in Q4 2025 and held it in 1 quarter.
  • Turning Point Benefit Group's CRISPR Therapeutics position peaked at $419 in Q4 2025.
  • 492 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.